Published in Biochem Mol Med on October 01, 1997
Potential mucolytic agents for mucinous ascites from pseudomyxoma peritonei. Invest New Drugs (2012) 0.75
Prevalence of lysosomal storage disorders. JAMA (1999) 9.06
Huntington disease-linked locus D4S111 exposed as the alpha-L-iduronidase gene. Somat Cell Mol Genet (1991) 2.23
Chromosomal localization of ARSB, the gene for human N-acetylgalactosamine-4-sulphatase. Hum Genet (1989) 1.95
Hunter syndrome: isolation of an iduronate-2-sulfatase cDNA clone and analysis of patient DNA. Proc Natl Acad Sci U S A (1990) 1.91
Glycosaminoglycan synthesis by cultured human skin fibroblasts after transformation with simian virus 40. J Biol Chem (1977) 1.77
A mouse model for mucopolysaccharidosis type III A (Sanfilippo syndrome). Glycobiology (1999) 1.67
Diagnosis of Maroteaux-Lamy syndrome by the use of radiolabelled oligosaccharides as substrates for the determination of arylsulphatase B activity. Biochem J (1986) 1.61
Genetic mapping of new RFLPs at Xq27-q28. Genomics (1991) 1.60
Structure of a human lysosomal sulfatase. Structure (1997) 1.57
Molecular genetics of mucopolysaccharidosis type I: diagnostic, clinical, and biological implications. Hum Mutat (1995) 1.54
Molecular genetics of mucopolysaccharidosis type IIIA and IIIB: Diagnostic, clinical, and biological implications. Hum Mutat (2001) 1.52
Human liver iduronate-2-sulphatase. Purification, characterization and catalytic properties. Biochem J (1990) 1.50
Human alpha-L-iduronidase: cDNA isolation and expression. Proc Natl Acad Sci U S A (1991) 1.48
The molecular-weight distribution of glycosaminoglycans. Biochem J (1973) 1.48
alpha-L-iduronidase, beta-D-glucuronidase, and 2-sulfo-L-iduronate 2-sulfatase: preparation and characterization of radioactive substrates from heparin. Carbohydr Res (1979) 1.45
High-resolution electrophoresis of urinary glycosaminoglycans: an improved screening test for the mucopolysaccharidoses. Anal Biochem (1982) 1.43
Enzymatic diagnosis of the mucopolysaccharidoses: experience of 96 cases diagnosed in a five-year period. Med J Aust (1982) 1.41
Coexistence of Gaucher disease type 1 and Joubert syndrome. J Med Genet (1998) 1.40
Enzyme replacement therapy for mucopolysaccharidosis VI from 8 weeks of age--a sibling control study. Clin Genet (2009) 1.39
Human alpha-L-iduronidase. 1. Purification, monoclonal antibody production, native and subunit molecular mass. Eur J Biochem (1985) 1.39
Gentamicin-mediated suppression of Hurler syndrome stop mutations restores a low level of alpha-L-iduronidase activity and reduces lysosomal glycosaminoglycan accumulation. Hum Mol Genet (2001) 1.36
The alkaline cleavage and borohydride reduction of cartilage proteoglycan. Biochem J (1973) 1.36
Human N-acetylgalactosamine-4-sulphate sulphatase. Purification, monoclonal antibody production and native and subunit Mr values. Biochem J (1987) 1.34
Human liver sulphamate sulphohydrolase. Determinations of native protein and subunit Mr values and influence of substrate agylcone structure on catalytic properties. Biochem J (1986) 1.33
Mucopolysaccharidosis VI (Maroteaux-Lamy syndrome): six unique arylsulfatase B gene alleles causing variable disease phenotypes. Am J Hum Genet (1994) 1.33
Correction of human mucopolysaccharidosis type-VI fibroblasts with recombinant N-acetylgalactosamine-4-sulphatase. Biochem J (1992) 1.32
Structure and sequence of the human alpha-L-iduronidase gene. Genomics (1992) 1.32
A fluorometric assay using 4-methylumbelliferyl alpha-L-iduronide for the estimation of alpha-L-iduronidase activity and the detection of Hurler and Scheie syndromes. Clin Chim Acta (1979) 1.27
A strategy for rapid sequencing of heparan sulfate and heparin saccharides. Proc Natl Acad Sci U S A (1999) 1.27
Highly sensitive sequencing of the sulfated domains of heparan sulfate. J Biol Chem (1999) 1.27
The alkali-labile linkage between keratan sulphate and protein. Biochem J (1974) 1.27
Human alpha-L-iduronidase. 2. Catalytic properties. Eur J Biochem (1985) 1.26
Enzyme replacement therapy in a feline model of Maroteaux-Lamy syndrome. J Clin Invest (1996) 1.24
Immunopurification and characterization of human alpha-L-iduronidase with the use of monoclonal antibodies. Biochem J (1989) 1.24
Cloning and expression of the gene involved in Sanfilippo B syndrome (mucopolysaccharidosis III B). Hum Mol Genet (1996) 1.22
The diagnosis of the Sanfilippo C syndrome, using monosaccharide and oligosaccharide substrates to assay acetyl-CoA: 2-amino-2-deoxy-alpha-glucoside N-acetyltransferase activity. Clin Chim Acta (1981) 1.22
Determination of acid alpha-glucosidase activity in blood spots as a diagnostic test for Pompe disease. Clin Chem (2001) 1.22
Human liver N-acetylglucosamine-6-sulphate sulphatase. Purification and characterization. Biochem J (1987) 1.21
Pharmacokinetic profile of recombinant human N-acetylgalactosamine 4-sulphatase enzyme replacement therapy in patients with mucopolysaccharidosis VI (Maroteaux-Lamy syndrome): a phase I/II study. Acta Paediatr Suppl (2005) 1.18
Identification of mutations in the alpha-L-iduronidase gene (IDUA) that cause Hurler and Scheie syndromes. Am J Hum Genet (1993) 1.18
Mucopolysaccharidosis type I: identification of 8 novel mutations and determination of the frequency of the two common alpha-L-iduronidase mutations (W402X and Q70X) among European patients. Hum Mol Genet (1994) 1.18
Risk factors for death in treated hypertensive patients. Report from the D.H.S.S. Hypertension Care Computing Project. Lancet (1979) 1.17
Sanfilippo type B syndrome (mucopolysaccharidosis III B): allelic heterogeneity corresponds to the wide spectrum of clinical phenotypes. Eur J Hum Genet (1999) 1.17
Recombinant human iduronate-2-sulphatase: correction of mucopolysaccharidosis-type II fibroblasts and characterization of the purified enzyme. Biochem J (1993) 1.17
Diagnosis of Sanfilippo type A syndrome by estimation of sulfamidase activity using a radiolabelled tetrasaccharide substrate. Clin Chim Acta (1982) 1.17
A common mutation for mucopolysaccharidosis type I associated with a severe Hurler syndrome phenotype. Hum Mutat (1992) 1.17
Human liver N-acetylglucosamine-6-sulphate sulphatase. Catalytic properties. Biochem J (1987) 1.16
Frequent deletions at Xq28 indicate genetic heterogeneity in Hunter syndrome. Hum Genet (1991) 1.15
Biochemical discrimination of Hurler and Scheie syndromes. Clin Sci (Lond) (1979) 1.13
Cloning of the sulphamidase gene and identification of mutations in Sanfilippo A syndrome. Nat Genet (1995) 1.13
alpha-L-iduronidase mutations (Q70X and P533R) associate with a severe Hurler phenotype. Hum Mutat (1992) 1.12
Enzyme replacement therapy in a feline model of MPS VI: modification of enzyme structure and dose frequency. Pediatr Res (2000) 1.12
alpha-L-Iduronidase deficiency in mucopolysaccharidosis type I against a radiolabelled sulfated disaccharide substrate derived from dermatan sulfate. Clin Genet (1984) 1.10
Defective lysosomal egress of free sialic acid (N-acetylneuraminic acid) in fibroblasts of patients with infantile free sialic acid storage disease. J Biol Chem (1989) 1.10
Identification and molecular characterization of alpha-L-iduronidase mutations present in mucopolysaccharidosis type I patients undergoing enzyme replacement therapy. Hum Mutat (2004) 1.09
Human glucosamine-6-sulfatase cDNA reveals homology with steroid sulfatase. Biochem Biophys Res Commun (1988) 1.09
Human N-acetylgalactosamine-4-sulphatase biosynthesis and maturation in normal, Maroteaux-Lamy and multiple-sulphatase-deficient fibroblasts. Biochem J (1990) 1.09
Enzyme replacement therapy from birth in a feline model of mucopolysaccharidosis type VI. J Clin Invest (1997) 1.08
Detection of Morquio A syndrome using radiolabelled substrates derived from keratan sulphate for the estimation of galactose 6-sulphate sulphatase. Clin Sci (Lond) (1983) 1.07
A cDNA clone for human glucosamine-6-sulphatase reveals differences between arylsulphatases and non-arylsulphatases. Biochem J (1992) 1.07
Effect of oxygen-derived reactive species on cartilage proteoglycan-hyaluronate aggregates. Biochem Int (1984) 1.07
Chromosomal localization of the human alpha-L-iduronidase gene (IDUA) to 4p16.3. Am J Hum Genet (1990) 1.05
The structure and composition of cartilage keratan sulphate. Biochem J (1974) 1.04
Effect of high dose, repeated intra-cerebrospinal fluid injection of sulphamidase on neuropathology in mucopolysaccharidosis type IIIA mice. Genes Brain Behav (2008) 1.04
Genotype-phenotype correlations in mucopolysaccharidosis type I using enzyme kinetics, immunoquantification and in vitro turnover studies. Biochim Biophys Acta (1998) 1.04
Glycosaminoglycan accumulation and excretion in the mucopolysaccharidoses: characterization and basis of a diagnostic test for MPS. Mol Genet Metab (1998) 1.03
A novel missense mutation in lysosomal sulfamidase is the basis of MPS III A in a spontaneous mouse mutant. Glycobiology (2001) 1.02
Characterization of a deletion at Xq27-q28 associated with unbalanced inactivation of the nonmutant X chromosome. Am J Hum Genet (1992) 1.02
Analysis of N-acetylgalactosamine-4-sulfatase protein and kinetics in mucopolysaccharidosis type VI patients. Am J Hum Genet (1991) 1.01
Studies on the polydispersity and heterogeneity of cartilage proteoglycans. Identification of 3 proteoglycan structures in bovine nasal cartilage. Biochem J (1975) 1.01
Iduronate-2-sulfatase gene mutations in 16 patients with mucopolysaccharidosis type II (Hunter syndrome). Hum Mol Genet (1993) 1.00
Identification, expression, and biochemical characterization of N-acetylgalactosamine-4-sulfatase mutations and relationship with clinical phenotype in MPS-VI patients. Am J Hum Genet (1996) 1.00
Gene expression profiling of bovine skeletal muscle in response to and during recovery from chronic and severe undernutrition. J Anim Sci (2006) 1.00
N-acetylglucosamine 6-sulfate residues in keratan sulfate and heparan sulfate are desulfated by the same enzyme. Biochem Int (1983) 1.00
Feline mucopolysaccharidosis type VI. Characterization of recombinant N-acetylgalactosamine 4-sulfatase and identification of a mutation causing the disease. J Biol Chem (1996) 0.99
Isolation and characterisation of a recombinant, precursor form of lysosomal acid alpha-glucosidase. Eur J Biochem (1995) 0.99
Improved concanavalin A-Sepharose elution by specific readsorption of glycoproteins. J Chromatogr (1983) 0.99
Human liver glucuronate 2-sulphatase. Purification, characterization and catalytic properties. Biochem J (1989) 0.99
Juvenile form of mucopolysaccharidosis VI (Maroteaux-Lamy syndrome). A C-terminal extension causes instability but increases catalytic efficiency of arylsulfatase B. J Biol Chem (1994) 0.99
alpha-L-iduronidase in normal and mucopolysaccharidosis-type-I human skin fibroblasts. Biochem J (1991) 0.98
Conditional tissue-specific expression of the acid alpha-glucosidase (GAA) gene in the GAA knockout mice: implications for therapy. Hum Mol Genet (2001) 0.98
Radiolabelled oligosaccharides as substrates for the estimation of sulfamidase and the detection of the Sanfilippo type A syndrome. Clin Chim Acta (1981) 0.98
Expression, purification and characterization of recombinant caprine N-acetylglucosamine-6-sulphatase. Biochem J (1997) 0.97
Sequence analysis of heparan sulphate and heparin oligosaccharides. Biochem J (1999) 0.97
Biochemical profiling to predict disease severity in metachromatic leukodystrophy. Mol Genet Metab (2009) 0.97
Histomorphometric analysis of the tibial growth plate in a feline model of mucopolysaccharidosis type VI. Calcif Tissue Int (1999) 0.97
Sequence of the human iduronate 2-sulfatase (IDS) gene. Genomics (1993) 0.97
Mucopolysaccharidosis type VI: Structural and clinical implications of mutations in N-acetylgalactosamine-4-sulfatase. Hum Mutat (2001) 0.97
Diagnosis of lysosomal storage disorders: evaluation of lysosome-associated membrane protein LAMP-1 as a diagnostic marker. Clin Chem (1997) 0.97
Human alpha-L-fucosidase: complete coding sequence from cDNA clones. Biochem Biophys Res Commun (1989) 0.96
Enzyme replacement therapy in Mucopolysaccharidosis VI: evidence for immune responses and altered efficacy of treatment in animal models. Biochim Biophys Acta (1997) 0.96
Characteristics of a lysosomal membrane transport system for tyrosine and other neutral amino acids in rat thyroid cells. J Biol Chem (1986) 0.96
Delivery of recombinant proteins via the cerebrospinal fluid as a therapy option for neurodegenerative lysosomal storage diseases. Int J Clin Pharmacol Ther (2009) 0.96
Joint analysis of multiple cDNA microarray studies via multivariate mixed models applied to genetic improvement of beef cattle. J Anim Sci (2004) 0.96
Enzyme replacement therapy for mucopolysaccharidosis VI: long-term cardiac effects of galsulfase (Naglazyme®) therapy. J Inherit Metab Dis (2012) 0.95